WINT - Long Setup Watch for a break of 2.42. Stop signal 1.92, First target 3.32, 2nd target momentum.
WINT
WINT - Ready to Double 😵-Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target.
-Windtree Therapeutics is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. The company's technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant without invasive procedures.
-Windtree's development program utilizing its proprietary technology platform is AEROSURF that is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
Windtree Therapeutics Inc 🧙Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF that is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
WINT - Long Setup Fallen Angel with Recent Insider Buying. Stop signal 1.96. Target 1 @ 2.87, Target 2 @ 3.93. Target
3@ 6.93.
the headlines say it all, short term Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases.
